At the time of writing, Boston Scientific Corp [BSX] stock is trading at $98.14, up 0.08%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BSX shares have lost -0.09% over the last week, with a monthly amount drifted -7.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Boston Scientific Corp [NYSE: BSX] stock has seen the most recent analyst activity on September 08, 2025, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $125 for it. Previously, Leerink Partners started tracking the stock with Outperform rating on June 16, 2025, and set its price target to $118. On April 16, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $113 on the stock. Deutsche Bank upgraded its rating to a Buy but stick to its price target of $108 on January 10, 2025. Needham downgraded its rating to a Hold. Goldman started tracking with a Buy rating for this stock on May 30, 2024, and assigned it a price target of $90. In a note dated February 01, 2024, Mizuho upgraded a Buy rating on this stock and boosted its target price from $65 to $80.
For the past year, the stock price of Boston Scientific Corp fluctuated between $80.64 and $109.50. Currently, Wall Street analysts expect the stock to reach $121 within the next 12 months. Boston Scientific Corp [NYSE: BSX] shares were valued at $98.14 at the most recent close of the market. An investor can expect a potential return of 23.29% based on the average BSX price forecast.
Analyzing the BSX fundamentals
According to Boston Scientific Corp [NYSE:BSX], the company’s sales were 18.49B for trailing twelve months, which represents an 22.84% jump. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.11 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 96.67 points at the first support level, and at 95.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 98.95, and for the 2nd resistance point, it is at 99.77.
Ratios To Look Out For
It is important to note that Boston Scientific Corp [NYSE:BSX] has a current ratio of 1.37. In addition, the Quick Ratio stands at 0.82 and the Cash Ratio stands at 0.1. Considering the valuation of this stock, the price to sales ratio is 7.86, the price to book ratio is 6.48 and price to earnings (TTM) ratio is 58.41.
Transactions by insiders
Recent insider trading involved Fitzgerald Joseph Michael, EVP & Group Pres, Cardiology, that happened on Sep 02 ’25 when 50000.0 shares were sold. Officer, JOSEPH M FITZGERALD completed a deal on Sep 02 ’25 to buy 50000.0 shares. Meanwhile, EVP & Group Pres, Cardiology Fitzgerald Joseph Michael sold 50000.0 shares on Aug 01 ’25.
